Key result
Bone marrow cell therapy reduces mortality and HF hospitalizations despite failing to meaningfully boost LVEF.
Meta-Analysis
Answers are grounded in this paper and cite their sources.
Meta-analyses of cell therapy trials for heart disease have yielded discrepant results. To resolve limitations associated with meta-analyses, such as imprecision and accumulation of random errors, we conducted trial sequential analysis (TSA). Randomized controlled trials that administered autologous bone marrow-derived cells to patients who suffered acute myocardial infarction (AMI) or heart failure (HF) were included. TSA has been applied to two clinical outcomes, all-cause mortality and hospitalization for HF, and to left ventricular ejection fraction (LVEF), as a surrogate of heart function. The results suggest that there is evidence of reduction of the risk of mortality and hospitalization in HF, but insufficient evidence to determine treatment effect in AMI. Moreover, the treatment does not improve LVEF by more than a mean difference of 4% when administered to either AMI or HF patients. The required number of participants to include in a meta-analysis to detect treatment effect was also estimated.
No takes yet. Share an insight, caveat, or question.
Fisher et al. (2016) conducted a meta-analysis in Acute myocardial infarction (AMI) or heart failure (HF). Autologous bone marrow-derived cells was evaluated on All-cause mortality, hospitalization for HF, and left ventricular ejection fraction (LVEF) (MD 4%). Autologous bone marrow-derived cell therapy reduced mortality and HF hospitalization in HF, but did not improve LVEF by >4% mean difference in either AMI or HF patients.
Synapse has enriched 10 related papers. Consider them for comparative context: